Aptamers: Potential applications to pancreatic cancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 5, 2011, Pages 434-441

  Rialon, Kristy L ^a   White, Rebekah R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aptamer; Cancer therapy; Pancreatic cancer; RNA therapeutic; SELEX

Indexed keywords

AGRO 100; ANTINEOPLASTIC AGENT; APTAMER; AX 102; BEVACIZUMAB; CETUXIMAB; ERLOTINIB; GEMCITABINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MUCIN 1; NOX E36; PANITUMUMAB; PEGAPTANIB; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CANCER THERAPY; COLON CANCER; COLORECTAL CANCER; COMBINATORIAL CHEMISTRY; DRUG ISOLATION; DRUG TARGETING; HEMANGIOPERICYTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; LUNG CARCINOMA; LYMPHOMA; MEDICAL RESEARCH; MELANOMA; MYELOID LEUKEMIA; NONHUMAN; PANCREAS CANCER; PHOTOTHERAPY; PROSTATE CANCER; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; STOMACH CANCER; SYNOVIAL SARCOMA; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER;

EID: 79958122939     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011795677472     Document Type: Review

References (124)

1. Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer Statistics, 2010. CA Cancer J Clin, 2010, 60, 277-300.
2. Burris, H.A.I., Moore, M.J., Andersen, J., Green, M.R., Rothen-berg, M.L., Modiano, M.R., Cripps, M.C., Portenoy, R.K., Storni-olo, A.M., Tarassoftt, P., Nelson, R., Dorr, F.A., Stephens, C.D., Von Hoff, D.D., Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial. J. Clin. Oncol, 1997,15, 2403-2413.
3. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., Kabbinavar, F., Bevacizumab plus irinotecan, fluorouracil, and leukcovorin for metastatic colorectal cancer. New England Journal of Medicine, 2004 350, 2335-2342.
4. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A., Shenkier, T., Cella, D., Davidson, N.E., Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine, 2007, 357, 2666-2676.
5. Miller, K.D., Chap, L.I., Holmes, F.A., Cobleigh, M.A., Marcom, P.K., Fehrenbacher, L., Dickler, M., Overmoyer, B.A., Reimann, J.D., Sing, A.P., Langmuir, V., Rugo, H.S., Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. Journal of Clinical Oncology, 2005, 23, 792-799.
6. Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Lilenbaum, R., Johnson, D.H., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine, 2006, 355, 2542-2550.
7. Kindler, H.L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcachy, M.F., O'Reilly, E., Wozniak, T.F., Picus, J., Bhargava, P., Mayer, R.J., Schilsky, R.L., Goldberg, R.M., Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol, 2010, 28, 3617-3622.
8. Ryu, B., Jones, J., Hollingsworth, M.A., Hruban, R.H., Kern, S.E., Invasion-specific Genes in Malignancy: Serial Analysis of Gene Expression Comparisons of Primary and Passaged Cancers. Cancer Research, 2001, 61, 1833-1838.
9. Seymour, A.B., Hruban, R.H., Redston, M., Caldas, C, Powell, S.M., Kinzler, K.W., Yeo, C.J., Kern, S.E., Allelotype of Pancreatic Adenocarcinoma. Cancer Research, 1994, 54, 2761-2764.
10. Muerkoster, S., Wegehenkel, K., Arlt, A., Witt, M., Sipos, B., Kruse, M., Sebens, T., Kloppel, G., Kalthoff, H., Folsch, U.R., Schafer, H., Tumor Stroma Interactions Induce Chemoresistance in Pancreatic Ductal Carcinoma Cells Involving Increased Secretion and Paracrine Effects of Nitric Oxide and Interleukin-1B. Cancer Research, 2004, 64, 1331-1337.
11. Yauch, R.L., Gould, S.E., Scales, S.J., Tang, T., Tian, H., Ahn, C.P., Marshall, D., Fu, L., Januario, T., Kallop, D., Nannini-Pepe, M., Kotkow, K., Marsters, J.C., Rubin, L.L., de Sauvage, F.J., A paracrine requirement for hedgehog signaling in cancer. Nature, 2008, 455, 406-410.
12. Bailey, J.M., Swanson, B.J., Hamada, T., Eggers, J.P., Singh, P.K., Caffery, T., Ouellette, M.M., Hollingsworth, M.A., Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res, 2008, 14, 5995-6004.
13. Olive, K.P., Jacobetz, M.A., Davidson, C.J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M.A., Caldwell, M.E., Allard, D., Frese, K.K., DeNicola, G., Feig, C, Combs, C, Winter, S.P., Ireland-Zecchini, H., Reichelt, S., Howat, W.J., Chang, A., Dhara, M., Wang, L., Rückert, F., Grutzmann, R., Pilar-sky, C, Izeradjene, K., Hingorani, S.R., Huang, P., Davies, S.E., Plunkett, W., Egorin, M., Hruban, R.H., Whitebread, N., McGovern, K., Adams, J., Iacobuzio-Donahue, C, Griffiths, J., Tuvesan, D.A., Inhibition of Hedgehog Signalizing Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science, 2009, 324, 1457-1461.
14. Ireson, C.R., Kelland, L.R., Discovery and development of anticancer aptamers. Mol Cancer Ther, 2006, 5, 2957-2962.
15. Jayasena, S.D., Aptamers: An emerging class of molecules that rival antibodies in diagnostics. Clin Chem, 1999, 45, 1628-1650.
16. Levy-Nissenbaum, E., Radovic-Moreno, A.F., Wang, A.Z., Langer, R., Farokhzad, O.C., Nanotechnology and aptamers: Applications in drug delivery. Trends Biotechnology, 2008, 26, 442-449.
17. Proske, D., Blank, M., Buhmann, R., Resch, A., Aptamers-Basic research, drug development, and clinical applications. Appl Microbiol Biotechnol, 2005, 69, 367-374.
18. Knudsen, S.M., Robertson, M.P., Ellington, A.D., In vitro selection using modified or unnatural nucleotides. Curr Protoc Nucleic Acid Chem, 2002. Chapter 9(Unit 9 6).
19. Okahira, S., Nishikawa, F., Nishikawa, S., Akazawa, T., Seya, T., Matsumoto, M., Interferon-beta induction through toll-like receptor 3 depends on double-stranded RNA structure. DNA Cell Biol, 2005, 24, 614-623.
20. Nimjee, S.M., Rusconi, C.P., Sullenger, B.A., Aptamers: an emerging class of therapeutics. Annu Rev Med, 2005, 56, 555-583.
21. Pestourie, C., Tavitian, B., Duconge, F., Aptamers against extracellular targets for in vivo applications. Biochimie, 2005, 89, 921-930.
22. Bouchard, P.R., Hutabarat, R.M., Thompson, K.M., Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxi-col, 2010, 50, 237-257.
23. Healy, J.M., Lewis, S.D., Kurz, M., Boomer, R.M., Thompson, K.M., Wilson, C., McCauley, T.G., Pharmacokinetics and biodis-tribution of novel aptamer compositions. Pharmaceutical Research, 2004, 21, 2234-2246.
24. Hicke, B.J., Marion, C., Chang, Y.F., Gould, T., Lynott, C.K., Parma, D., Schmidt, P.G., Warren, S., Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem., 2001, 276, 48644-48654.
25. Hicke, B.J., Stephens, A.W., Gould, T., Chang, Y., Lynott, C.K., Heil, J., Borkowski, S., Hilger, C., Cook, G., Warren, S., Schmidt, P.G., Tumor targeting by an Aptamer. The Journal of Nuclear Medicine, 2006, 47, 668-678.
26. Ng, E.W., Shima, D.T., Calias, P., Cunningham, E.T., Jr., Guyer, D.R., Adamis, A.P., Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov, 2006, 5, 123-132.
27. Phillips, J.A., Lopez-Colon, D., Zhu, Z., Xu, Y., Tan, W., Applications of aptamers in cancer cell biology. Anal Chim Acta, 2008, 621, 101-108.
28. Rusconi, C.P., Scardino, E., Layzer, J., Pitoc, G.A., Ortel, T.L., Monroe, D., Sullenger, B.A., RNA aptamers as reversible antagonists of coagulation factor IXa. Nature, 2002, 419, 90-94.
29. White, R.R., Sullenger, B.A., Rusconi, C.P., Developing aptamers into therapeutics. J. Clin. Invest., 2000, 106, 929-934.
30. Ellington, A.D., Szostak, J.W., In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346, 818-822.
31. Tuerk, C., Gold, L., Systemic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4DNA polymerase. Science, 1990, 249, 505-510.
32. Ferrara, N., Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev., 2004, 25, 581-611.
33. Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1995, 1, 27-31.
34. Itakura, J., Ishiwata, T., Friess, H., Fujii, H., Matsumoto, Y., Bu-chler, M.W., Korc, M., Enhanced expression of vascular endothe-lial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res, 1997, 3, 1309-1316.
35. Lindahl, P., Johansson, B.R., Leveen, P., Betsholtz, C., Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science, 1997, 277, 242-245.
36. Sato, N., Beitz, J.G., Kato, J., Yamamoto, M., Clark, J.W., Cala-bresi, P., Kelton, A.J., Jr., Platelet-derived growth factor indirectly stimulats angiogenesis in vitro. Am. J. Pathol., 1994, 145, 1023-1029.
37. Sennino, B., Falcon, B.L., McCauley, D., Le, T., McCauley, T., Kurz, J.C., Haskell, A., Epstein, D.M., McDonald, D.M., Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res, 2007, 67, 7358-7367.
38. Ebert, M., Yokoyama, M., Friess, H., Kobrin, M.S., Buchler, M.W., Korc, M., Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer, 1995, 62, 529-535.
39. Griffin, R.J., Williams, B.W., Wild, R., Cherrington, J.M., Park, H., Song, C.W., Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res, 2002, 62, 1702-1706.
40. Srivastava, M., Pollard, H.B., Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J, 1999, 13, 1911-1922.
41. Soundararajan, S., Wang, L., Sridharan, V., Chen, W., Courtenay-Luck, N., Jones, D., Spicer, E.K., Fernandes, D.J., Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol Pharmacol, 2009, 76, 984-991.
42. Girvan, A.C., Teng, Y., Casson, L.K., Thomas, S.D., Juliger, S., Ball, M.W., Klein, J.B., Pierce, W.M., Jr., Barve, S.S., Bates, P.J., AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol. Cancer Ther., 2006, 5, 1790-1799.
43. Soundararajan, S., Chen, W., Spicer, E.K., Courtenay-Luck, N., Fernandes, D.J., The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res, 2008, 68, 2358-2365.
44. Laber, D.A., Sharma, V.R., Bhupalam, B., Taft, B., Hendler, F.J., Barnhart, K.M., Update on the first phase I study of AGRO100 in advanced cancer. J Clin Oncol, 2005, 23, 3064.
45. Hwang do, W., Ko, H.Y., Lee, J.H., Kang, H., Ryu, S.H., Song, I.C., Lee, D.S., Kim, S., A nucleolin-targeted multimodal nanopar-ticle imaging probe for tracking cancer cells using an aptamer. J. Nucl. Med., 2010, 51, 98-105.
46. Shieh, Y.A., Yang, S.J., Wei, M.F., Shieh, M.J., Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano, 2010, 4, 1433-1442.
47. Peng, L., Liang, J., Wang, H., Song, X., Rashid, A., Gomez, H.F., Corley, L.J., Abbruzzese, J.L., Fleming, J.B., Evans, D.B., Wang, H., High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res, 2010, 16, 3734-3742.
48. Sato, T.N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fuji-wara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., Qin, Y., Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature, 2002, 376, 70-74.
49. Holash, J., Maisonpierre, P.C., Compton, D., Boland, P., Alexander, C.R., Zagzag, D., Yancopoulous, G.D., Wiegand, S.J., Vessel cooption, regression, and growth in tumors mediated by angio-poietins and VEGF. Science, 1999, 284, 1994-1998.
50. White, R.R., Shan, S., Rusconi, C.P., Shetty, G., Dewhirst, M.W., Konton, C.D., Sullenger, B.A., Inhibition of rat corneal angiogene-sis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc. Natl. Acad. Sci. USA, 2003, 100, 5028-5033.
51. Sarraf-Yazdi, S., Mi, J., Moeller, B.J., Niu, X., White, R.R., Kon-tos, C.D., Sullenger, B.A., Dewhirst, M.W., Clary, B.M., Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. J Surg Res, 2008, 146, 16-23.
52. Ogawa, K., Utsunomiya, T., Mimori, K., Tanaka, F., Haraguchi, N., Inoue, H., Murayama, S., Mori, M., Differential gene expression profiles of radioresistant pancreatic cancer cell lines established by fractionated irradiation. Int J Oncol, 2006, 28, 705-713.
53. Durkin, A.J., Bloomston, M., Yeatman, T.J., Gilbert-Barness, E., Cojita, D., Rosemurgy, A.S., Zervos, E.E., Differential expression of the Tie-2 receptor and its ligands in human pancreatic tumors. J Am Coll Surg, 2004, 199, 724-731.
54. Maasch, C., Buchner, K., Eulberg, D., Vonhoff, S., Klussmann, S., Physiocochemical stability of NOX-E36, a 40mer L-RNA (Spiegelmer) for therapeutic applications. Nucleic Acids Symp Ser (Oxf), 2008, 52, 61-62.
55. Klussmann, S., Nolte, A., Bald, R., Erdmann, V.A., Furste, J.P., Mirror-image RNA that binds D-adenosine. Nat Biotechnol, 1996, 14, 1112-1115.
56. Bottazzi, B., Polentarutti, N., Acero, R., Balsari, A., Boraschi, D., Ghezzi, P., Salmona, M., Mantovani, A., Regulation of the macro-phage content of neoplasms by chemoattractants. Science, 1983, 220, 210-212.
57. Shimada, M., Andoh, A., Araki, Y., Fujiyama, Y., Bamba, T., Ligation of the Fas antigen stimulates chemokine secretion in pancreatic cancer cell line PANC-1. J Gastroenterol Hepatol, 2001, 16, 1060-1067.
58. Takaya, H., Andoh, A., Shimada, M., Hata, K., Fujiyama, Y., Bamba, T., The expression of chemokine genes correlates with nuclear factor-kappaB activation of human pancreatic cancer cell lines. Pancreas, 2000, 21, 32-40.
59. Negus, R.P., Stamp, G.W., Hadley, J., Balkwill, F.R., Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol, 1997, 150, 1723-1734.
60. Benchimol, S., Fuks, A., Jothy, S., Beauchemin, N., Shirota, K., Stanners, C.P., Carcinoembryonic antigen, a human tumor marker, functions as an intracellular adhesion molecule. Cell, 1989, 57, 327-334.
61. Wang, L., Liu, B., Yin, H., Wei, J., Qian, X., Yu, L., Selection of DNA aptamer that specific binding human carcinoembryonic antigen in vitro. Journal of Nanjing Medical University, 2007, 21, 277-281.
62. Hashemi Tabar, G.R., Smith, C.L., DNA aptamers selected as molecular probes for diagnosis of cancereous cells. World Appl. Sci. J., 2010, 8, 16-21.
63. Albers, G.H., Fleuren, G., Escribano, M.J., Nap, M., Immunohisto-chemistry of CEA in the human pancreas during development, in the adult, chronic pancreatitis, and pancreatic adenocarcinoma. Am J Clin Pathol, 1988, 90, 17-22.
64. Yamaguchi, K., Enjoji, M., Tsuneyoshi, M., Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immuno-histochemical observation for CEA and CA19-9. J Surg Oncol, 1991, 47, 148-154.
65. Zhou, J., Hu, L., Yu, Z., Zheng, J., Yang, D., Bouvet, M., Hoffman, R.M., Marker expression in circulating cancer cells of pancreatic cancer patients. J Surg Res, 2010. Jun 1 [Epub ahead of print]: p. 1-6.
66. Brugge, W.R., Lewandrowski, K., Lee-Lewandrowski, E., Centeno, B.A., Szydlo, T., Regan, S., del Castillo, C.F., Warshaw, A.L., Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology, 2004, 126, 1330-1336.
67. Kaushal, S., McElroy, M.K., Luiken, G.A., Talamini, M.A., Moossa, A.R., Hoffman, R.M., Bouvet, M., Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J Gastrointest Surg, 2008, 12, 1938-1950.
68. Altschuler, Y., Kinlough, C.L., Poland, P.A., Bruns, J.B., Apodaca, G., Weisz, O.A., Hughey, R.P., Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol Biol Cell, 2000, 11, 819-831.
69. Ceriani, R.L., Chan, C.M., Baratta, F.S., Ozzello, L., DeRosa, C.M., Habif, D.V., Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis. Int J Cancer, 1992, 51, 343-354.
70. Henderikx, P., Coolen-van Neer, N., Jacobs, A., van der Linden, E., Arends, J.W., Mullberg, J., Hoogenboom, H.R., A human immu-noglobulin G1 antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized. Am J Pathol, 2002, 160, 1597-1608.
71. Burchell, J.M., Mungul, A., Taylor-papadimitriou, J., O-linked glycosylation in the mammary gland: changes that occur during malignancy. J Mammary Gland Biol Neoplasia, 2001, 6, 355-364.
72. Brayman, M., Thathiah, A., Carson, D.D., MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Re-prod Biol Endocrinol, 2004, 2, 4.
73. Gendler, S.J., MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia, 2001, 6, 339-353.
74. Ferreira, C.S., Cheung, M.C., Missailidis, S., Bisland, S., Gariepy, J., Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Research, 2009. 37(3): p. 866-876.
75. Sefton, B.M., Hunter, T., Tyrosine protein kinases. Adv Cyclic Nucleotide Protein Phosphorylation Res, 1984, 18, 195-226.
76. Thompson, D.M., Gill, G.N., The EGF receptor: structure, regulation and potential role in malignancy. Cancer Surv, 1985, 4, 767-788.
77. Alroy, I., Yarden, Y., The ErbB signaling network in embryogene-sis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett, 1997, 410, 83-86.
78. Brown, K.D., The epidermal growth factor/transforming growth factor-alpha family and their receptors. Eur J Gastroenterol Hepa-tol, 1995, 7, 914-922.
79. Casalini, P., Iorio, M.V., Galmozzi, E., Menard, S., Role of HER receptors family in development and differentiation. J Cell Physiol, 2004, 200, 343-350.
80. Fichera, A., Little, N., Jagadeeswaran, S., Dougherty, U., Sehdev, A., Mustafi, R., Cerda, S., Yuan, W., Khare, S., Tretiakova, M., Gong, C., Tallerico, M., Cohen, G., Joseph, L., Hart, J., Turner, J.R., Bissonnette, M., Epidermal growth factor receptor signaling is requried for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res, 2008, 67, 827-835.
81. Sainsbury, J.R., Farndon, J.R., Sherbet, G.V., Harris, A.L., Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet, 1985, 16, 364-366.
82. Shin, D.M., Ro, J.Y., Hong, W.K., Hittelman, W.N., Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res, 1994, 54, 3153-3159.
83. Boonstra, J., Rijken, P., Humbel, B., Cremers, F., Verkleij, A., van Bergen en Henegouwen, P., The epidermal growth factor. Cell Biol Int, 1995, 19, 413-430.
84. Matsuda, K., Idezawa, T., You, X.J., Kothari, N.H., Fan, H., Korc, M., Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res, 2002, 62, 5611-5617.
85. Murphy, L.O., Cluck, M.W., Lovas, S., Otvos, F., Murphy, R.F., Schally, A.V., Permert, J., Larsson, J., Knezetic, J.A., Adrian, T.E., Pancreatic cancer cells requrie an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. Br. J. Cancer, 2001, 84, 926-935.
86. Yamanaka, Y., Friess, H., Kobrin, M.S., Buchler, M., Beger, H.G., Korc, M., Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res, 1993, 13, 565-569.
87. Yu, Y., Rishi, A.K., Turner, J.R., Liu, D., Black, E.D., Moshier, J.A., Majumdar, A.P., Cloning of a novel EGFR-related peptide: a putative negative regulator of EGFR. Am J Physiol Cell Physiol, 2001, 280, 1083-1089.
88. Feng, J., Adsay, N.V., Kruger, M., Ellis, K.L., Nagothu, K., Ma-jumdar, A.P., Sarkar, F.H., Expression of ERRP in normal and neoplastic pancreata and its relationship to clinicopathologic parameters in pancreatic adenocarcinoma. Pancreas, 2002, 25, 342-349.
89. Zhang, Y., Banerjee, S., Wang, Z., Marciniak, D.J., Majumdar, A.P.N., Sarkar, F.H., Epidermal growh factor receptor-related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells. Cancer Res, 2005, 65, 3877-3882.
90. Moore, M.J., Goldstein, D., Hamm, J., Figer, A., Hecht, J.R., Gall-inger, S., Au, H.J., Murawa, P., Walde, D., Wolff, R.A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasyn-ski, M., Parulekar, W; National Cancer Institute of Canada Clinical Trials Group, Erlotinib plus gemcitabine compared with gemcit-abine alone in patients wtih advanced panreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 2007, 25, 1960-1966.
91. Ferreira, C.S.M., Cheung, M.C., Missailidis, S., Bisland, S., Ga-riepy, J., Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Research, 2009, 37, 866-876.
92. Shangguan, D., Li, Y., Tang, Z., Cao, Z.C., Chen, H.W., Mal-likaratchy, P., Sefah, K., Yang, C.J., Tan, W., Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. USA, 2006, 103, 11838-11843.
93. Blank, M., Weinschenk, T., Priemer, M., Schluesener, H., Systematic evoluation of a DNA aptamer binding to rat brain tumor mi-crovessels. selective targeting of endothelial regulatory protein. J Biol Chem, 2001, 276, 16464-16468.
94. Wang, C., Zhang, M., Yang, G., Zhang, D., Ding, H., Wang, H., Fan, M., Shen, B., Shao, N., Single-stranded DNA aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment. J Biotechnol, 2003, 102, 15-22.
95. Daniels, D.A., Chen, H., Hicke, B.J., Swiderek, K.M., Gold, L., A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc. Natl. Acad. Sci. USA, 2003, 100, 15416-15421.
96. Cerchia, L., Duconge, F., Pestourie, C., Boulay, J., Aissouni, Y., Gombert, K., Tavitian, B., de Franciscis, V., Libri, D., Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol, 2005, 3, e123.
97. Shangguan, D., Meng, L., Cao, Z.C., Xiao, Z., Fang, X., Li, Y., Cardona, D., Witek, R.P., Liu, C., Tan, W., Identification of liver cancer-specific aptamers using whole live cells. Anal Chem, 2008, 80, 721-728.
98. Cerchia, L., de Franciscis, V., Targeting cancer cells with nucleic acid aptamers. Trends Biotechnology, 2010, 28, 517-525.
99. Gschwind, A., Fischer, O.M., Ullrich, A., The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer, 2004, 4, 361-370.
100. Jhiang, S.M., The RET proto-oncogene in human cancers. Onco-gene, 2000, 19, 5590-5597.
101. Hansford, J.R., Mulligan, L.M., Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J. Med. Genet., 2000, 37, 817-827.
102. Dueck, M., Riedl, S., Hinz, U., Tandara, A., Moller, P., Herfath, C., Faissner, A., Detection of tenascin-C isoforms in colorectal mu-cosa, ulcerative colitis, carcinomas and liver metastases. Int J Cancer, 1999, 82, 477-483.
103. Chen, H.W., Medley, C.D., Sefah, K., Shangguan, D., Tang, Z., Meng, L., Smith, J.E., Tan, W., Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem, 2008, 3, 991-1001.
104. Mi, J., Liu, Y., Rabbani, Z.N., Yang, Z., Sullenger, B.A., Clary, B.M., In vivo selection of tumor-targeting RNA motifs. Nature Chemical Biology, 2009, 6, 22-24.
105. Rossow, K.L., Janknecht, R., Synergism between p68 RNA heli-case and the transcriptional coactivators CBP and p300. Oncogene, 2003, 22, 151-156.
106. Kumar, P., Wu, H., McBride, J.L., Jung, K.E., Kim, M.H., Davidson, B.L., Lee, S.K., Shankar, P., Manjunath, N., Transvascular delivery of small interfering RNA to the central nervous sytem. Nature, 2007, 448, 39-43.
107. Meade, B.R., Dowdy, S.F., Exogenous siRNA delviery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev, 2007, 59, 134-140.
108. Song, E., Zhu, P., Lee, S.K., Chowdury, D., Kussman, S., Dykx-hoorn, D.M., Feng, Y., Palliser, D., Weiner, D.B., Shankar, P., Marasco, W.A., Lieberman, J., Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol, 2005, 23, 709-717.
109. Peer, D., Zhu, P., Carman, C.V., Lieberman, J., Shimaoka, M., Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc. Natl. Acad. Sci. USA, 2007, 104, 4095-4100.
110. Rozema, D.B., Lewis, D.L., Wakefield, D.H., Wong, S.C., Klein, J.J., Roesch, P.L., Bertin, S.L., Reppen, T.W., Chu, Q., Blokhin, A.V., Hagstrom, J.E., Wolff, J.A., Dyamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. USA, 2007, 104, 12982-12987.
111. McNamara, J.O., II, Andrechek, E.R., Wang, Y., Viles, K.D., Rempel, R.E., Gilboa, E., Sullenger, B.A., Giangrande, P.H., Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nature Biotechnology, 2006, 24, 1005-1015.
112. Reagan-Shaw, S., Ahmad, N., Silencing of polo-like kinase (Plk) 1 via siRNA causese induction apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J, 2005, 19, 611-613.
113. Takai, N., Hamanaka, R., Yoshimatsu, J., Miyakawa, I., Polo-like kinases (Plks) and cancer. Oncogene, 2005, 24, 287-291.
114. Eckerdt, F., Yuan, J., Strebhardt, K., Polo-like kinases and onco-genesis. Oncogene, 2005, 24, 267-276.
115. Cory, S., Adams, J.M., Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell, 2005, 8, 5-6.
116. Wullner, U., Neef, I., Eller, A., Kleines, M., Tur, M.K., Barth, S., Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets, 2008, 8, 554-565.
117. Morimoto, H., Bonavida, B., Diphtheria toxin- and Pseudomonas A toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alpha. J immunol., 1992, 149, 2089-2094.
118. Farokhzad, O.C., Cheng, J., Teply, B.A., Sherifi, I., Jon, S., Kan-toff, P.W., Richie, J.P., Langer, R., Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA, 2006, 103, 6315-6320.
119. Dhar, S., Gu, F.X., Langer, R., Farokhzad, O.C., Lippard, S.J., Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA, 2008, 105, 17356-17361.
120. Chu, T.C., Marks, J.W. 3rd, Lavery, L.A., Faulkner, S., Rosen-blum, M.G., Ellingon, A.D., Levy, M., Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res, 2006, 66, 5989-5992.
121. Bagalkot, V., Zhang, L., Levy-Nissenbaum, E., Jon, S., Kantoff, P.W., Langer, R., Farokhzad, O.C., Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bifluorescence energy transfer. Nano. Lett., 2007, 7, 3065-3070.
122. Huang, Y.F., Sefah, K., Bamrungsap, S., Chang, H.T., Tan, W., Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. Langmuir, 2008, 24, 11860-11865.
123. Borbas, K.E., Ferreira, C.S., Perkins, A., Bruce, J.I., Missailidis, S., Design and synthesis of mono- and multimeric targeted radiophar-maceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. Bioconjub Chem, 2007, 18, 1205-1212.
124. 99mTc and biodistribution in MCF-7 tumour-bearing mice. Nucl. Med. Biol., 2009, 703-710.